Article Text

Download PDFPDF
HIV testing in Europe: how can primary care contribute?
  1. Werner Leber1,
  2. Jane Anderson2,
  3. Chris Griffiths1
  1. 1Centre for Primary Care and Public Health, Queen Mary University of London, London, UK
  2. 2Homerton Sexual Health Services, Homerton University Hospital NHS Foundation Trust, London, UK
  1. Correspondence to Dr Werner Leber, Centre for Primary Care and Public Health, Queen Mary University of London, London, E1 2AB UK; w.leber{at}qmul.ac.uk

Statistics from Altmetric.com

Undiagnosed HIV infection is a major challenge in the quest to achieve an AIDS-free world. Undetected HIV and late diagnosis are associated with ill health, increased risk of death from HIV/AIDS and onward viral transmission, constituting a substantial burden to public health budgets worldwide. Roughly half of the 2.2 million people with HIV in Europe are undiagnosed.1 These figures are mirrored in the UK and the USA, where almost one-quarter of >100 000 and one-sixth of 1.1 million people with HIV remain undiagnosed, respectively.2 ,3 Unacceptably high proportions (up to 53%) of patients are diagnosed late (CD4 cell count <350 cells/μL).1 Expansion of HIV testing is therefore key to improving HIV outcomes.

Early diagnosis followed by immediate antiretroviral treatment reduces HIV-related illness and death. Recent data from both the Strategic Timing of AntiRetroviral Treatment and TEMPRANO ANRS 12136 trials have unambiguously shown that these benefits also extend to patients diagnosed at CD4 of ≥500/μL.4 ,5 Timely diagnosis and treatment have additionally been shown to reduce onward transmission at both individual and population levels, indicating that treatment and prevention are inextricably linked,6 and routine HIV testing is considered cost-effective even when combining one-time HIV screening for the whole population with more frequent testing in subpopulations at risk.7

Given these facts, why …

View Full Text

Footnotes

  • Contributors All three co-authors contributed to writing this manuscript.

  • Competing interests JA reports fees and non-financial support from Bristol-Myers Squibb, grants and personal fees from Gilead Sciences, personal fees from ViiV, personal fees from Merck Sharp & Dohme, grants from Janssen, and personal fees from AbbVie, outside the submitted work.

  • Funding The research was funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care North Thames at Barts Health NHS Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles